more 4.5 | 1,267 Hot Deal 67% 3,897 1,299 Buy at 1,234 Apply offers for maximum savings Apply offers for maximum savings
Lilly shares were up 5% in morning trading Tuesday
Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, et al
Clinical research involving approximately 900 participants across six human trials has validated AOD-9604 s selective fat-targeting effects
10.3389/fcvm.2022.1019120 80
Building on these research findings, Eli Lilly developed a dual agonist targeting GLP-1R/GIPR, called tirzepatide, which was approved by the FDA in 2022 and showed promising therapeutic effects for T2D and obesity